EFG International AG Acquires New Position in Illumina, Inc. $ILMN

EFG International AG acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 4,561 shares of the life sciences company’s stock, valued at approximately $802,000.

Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Illumina in the 2nd quarter valued at $3,374,423,000. Primecap Management Co. CA bought a new stake in shares of Illumina during the 2nd quarter worth $617,981,000. WCM Investment Management LLC lifted its position in shares of Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after buying an additional 1,851,848 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in Illumina in the second quarter valued at about $293,846,000. Finally, Invesco Ltd. boosted its stake in Illumina by 97.0% in the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock valued at $360,426,000 after buying an additional 1,352,731 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Trading Up 1.3%

Shares of ILMN stock opened at $227.69 on Friday. Illumina, Inc. has a twelve month low of $88.00 and a twelve month high of $231.81. The stock’s fifty day simple moving average is $192.98 and its 200 day simple moving average is $155.18. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The firm has a market capitalization of $34.38 billion, a P/E ratio of 42.48, a P/E/G ratio of 3.16 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period last year, the company earned $1.19 earnings per share. The business’s quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts predict that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Keith A. Meister sold 457,858 shares of Illumina stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the sale, the director directly owned 2,372,694 shares in the company, valued at $474,776,069.40. This trade represents a 16.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total transaction of $197,840.16. Following the sale, the senior vice president directly owned 14,023 shares in the company, valued at $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 2,034,688 shares of company stock valued at $417,970,281. 2.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages have commented on ILMN. JPMorgan Chase & Co. boosted their target price on Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Zacks Research raised shares of Illumina from a “hold” rating to a “strong-buy” rating in a report on Monday, August 3rd. Citigroup upped their price objective on shares of Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research report on Monday, August 3rd. Finally, Evercore reissued an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Illumina currently has an average rating of “Hold” and a consensus target price of $188.40.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.